Valuation: ProMIS Neurosciences, Inc.

Market Cap 105M 74.62M 66.72M 61.73M 55.89M 7.1B 106M 743M 294M 3.71B 280M 274M 11.76B P/E 2026 *
-1.66x
P/E 2027 * -2.13x
Enterprise Value 105M 74.62M 66.72M 61.73M 55.89M 7.1B 106M 743M 294M 3.71B 280M 274M 11.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.13%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-0.97%
Current month-24.88%
1 month-23.47%
3 months-30.46%
6 months-26.58%
Current year+19.41%
1 week 7.74
Extreme 7.7426
9.31
1 month 7.74
Extreme 7.7426
11.57
Current year 6.72
Extreme 6.72
27.4
1 year 6.27
Extreme 6.27
27.4
3 years 6.27
Extreme 6.27
77.5
5 years 6.27
Extreme 6.27
245
10 years 6.27
Extreme 6.27
1,050
Manager TitleAgeSince
Chief Executive Officer 63 2023-12-29
Chief Tech/Sci/R&D Officer 74 2004-05-30
Director of Finance/CFO 69 2017-03-21
Director TitleAgeSince
Chairman 88 2014-06-11
Chairman 74 2012-10-02
Director/Board Member 63 2021-05-12
Date Insider Type Main position Quantity % Market Cap. Importance
8/5/26 Buy

Executive/Senior Manager

2,280 0.0254%
5/20/26 Free

Principal Accounting Officer

18,167 0.2026%
5/20/26 Free

Executive/Senior Manager

50,000 0.5576%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-0.97%-28.85%-82.12% 74.79M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+6.91%+9.79%+77.36% 54.78B
+0.47%+3.52%+9.71%+100.95% 53.49B
-1.55%+3.56%+26.63%+49.30% 45.98B
-1.72%+0.41%+17.83%+124.11% 42.94B
-1.62%+1.52%+218.87%+828.73% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+16.60%+58.50%+46.15% 23.67B
Average +0.39%+2.23%+39.51%+126.51% 38.32B
Weighted average by Cap. +0.20%+2.59%+44.32%+151.12%

Financials

2026 *2027 *
Net sales - -
Net income -63.93M -45.6M -40.78M -37.73M -34.16M -4.34B -64.98M -454M -180M -2.27B -171M -167M -7.18B -74.57M -53.19M -47.57M -44.01M -39.85M -5.06B -75.8M -530M -209M -2.65B -200M -195M -8.38B
Net Debt - -
Projected Income Statement - Annual - ProMIS Neurosciences, Inc.
Logo ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Employees
11
Date Price Change Volume
26-10-26 US$8.150 -2.28% 13,577
26-10-23 US$8.340 -7.13% 10,442
26-10-22 US$8.980 -1.64% 6,439
26-10-21 US$9.130 +12.86% 7,485
26-10-20 US$8.090 -1.70% 30,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ProMIS Neurosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.66CAD
Average target price
60.77CAD
Spread / Average Target
+420.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ProMIS Neurosciences, Inc.